Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
92% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. IMGN: No Debt )
IMGN' s 10-Year Cash to Debt Range
Min: 0.39   Max: 50356.33
Current: No Debt

0.39
50356.33
Equity to Asset 0.41
IMGN's Equity to Asset is ranked higher than
59% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMGN: 0.41 )
IMGN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.95
Current: 0.41

0.27
0.95
Interest Coverage No Debt
IMGN's Interest Coverage is ranked higher than
74% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMGN: No Debt )
IMGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -3.58
M-Score: -5.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -146.93
IMGN's Operating margin (%) is ranked higher than
69% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. IMGN: -146.93 )
IMGN' s 10-Year Operating margin (%) Range
Min: -3860   Max: -6.81
Current: -146.93

-3860
-6.81
Net-margin (%) -147.49
IMGN's Net-margin (%) is ranked higher than
69% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. IMGN: -147.49 )
IMGN' s 10-Year Net-margin (%) Range
Min: -3980   Max: -2.13
Current: -147.49

-3980
-2.13
ROE (%) -85.48
IMGN's ROE (%) is ranked higher than
61% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. IMGN: -85.48 )
IMGN' s 10-Year ROE (%) Range
Min: -257.81   Max: -2.3
Current: -85.48

-257.81
-2.3
ROA (%) -45.91
IMGN's ROA (%) is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. IMGN: -45.91 )
IMGN' s 10-Year ROA (%) Range
Min: -129.41   Max: -1.79
Current: -45.91

-129.41
-1.79
ROC (Joel Greenblatt) (%) -662.25
IMGN's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. IMGN: -662.25 )
IMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -666.37   Max: -48.97
Current: -662.25

-666.37
-48.97
Revenue Growth (3Y)(%) 35.70
IMGN's Revenue Growth (3Y)(%) is ranked higher than
94% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. IMGN: 35.70 )
IMGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -36.1   Max: 133.1
Current: 35.7

-36.1
133.1
EBITDA Growth (3Y)(%) -0.80
IMGN's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. IMGN: -0.80 )
IMGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -71.2   Max: 282.6
Current: -0.8

-71.2
282.6
EPS Growth (3Y)(%) -0.80
IMGN's EPS Growth (3Y)(%) is ranked higher than
80% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. IMGN: -0.80 )
IMGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.7   Max: 263.4
Current: -0.8

-75.7
263.4
» IMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IMGN Guru Trades in Q4 2013

PRIMECAP Management 12,675,427 sh (+0.58%)
Steven Cohen Sold Out
» More
Q1 2014

IMGN Guru Trades in Q1 2014

PRIMECAP Management 12,675,427 sh (unchged)
» More
Q2 2014

IMGN Guru Trades in Q2 2014

Jim Simons 415,440 sh (New)
PRIMECAP Management 11,922,396 sh (-5.94%)
» More
Q3 2014

IMGN Guru Trades in Q3 2014

PRIMECAP Management 11,918,396 sh (-0.03%)
Jim Simons 370,446 sh (-10.83%)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.86
IMGN's P/B is ranked higher than
62% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. IMGN: 8.86 )
IMGN' s 10-Year P/B Range
Min: 1.68   Max: 16.54
Current: 8.86

1.68
16.54
P/S 9.37
IMGN's P/S is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. IMGN: 9.37 )
IMGN' s 10-Year P/S Range
Min: 2.83   Max: 97.63
Current: 9.37

2.83
97.63
EV-to-EBIT -4.91
IMGN's EV-to-EBIT is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IMGN: -4.91 )
IMGN' s 10-Year EV-to-EBIT Range
Min: -43.7   Max: -2.2
Current: -4.91

-43.7
-2.2
Current Ratio 3.23
IMGN's Current Ratio is ranked higher than
66% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. IMGN: 3.23 )
IMGN' s 10-Year Current Ratio Range
Min: 0.51   Max: 60.86
Current: 3.23

0.51
60.86
Quick Ratio 3.17
IMGN's Quick Ratio is ranked higher than
67% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. IMGN: 3.17 )
IMGN' s 10-Year Quick Ratio Range
Min: 0.51   Max: 60.86
Current: 3.17

0.51
60.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.89
IMGN's Price/Net Cash is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. IMGN: 13.89 )
IMGN' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 179
Current: 13.89

0.9
179
Price/Net Current Asset Value 13.00
IMGN's Price/Net Current Asset Value is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. IMGN: 13.00 )
IMGN' s 10-Year Price/Net Current Asset Value Range
Min: 0.88   Max: 58.33
Current: 13

0.88
58.33
Price/Tangible Book 8.86
IMGN's Price/Tangible Book is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. IMGN: 8.86 )
IMGN' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 40
Current: 8.86

0.81
40
Price/Median PS Value 0.60
IMGN's Price/Median PS Value is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. IMGN: 0.60 )
IMGN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 10.94
Current: 0.6

0.2
10.94
Earnings Yield (Greenblatt) -20.40
IMGN's Earnings Yield (Greenblatt) is ranked higher than
66% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. IMGN: -20.40 )
IMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -20.4

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 101 146 151
EPS($) -0.71 -0.43 -0.31
EPS without NRI($) -0.71 -0.43 -0.31

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IMU.Germany,
Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: IMGN853, IMGN289, and IMGN529. It's IMGN853 product candidate is used for the treatment of ovarian cancer, endometrial cancer, and potentially other cancers that highly express folate receptor a, or FRa. It's EGFR-targeting ADC, IMGN289, is used for the treatment of cancers that highly express EGFR which include squamous cell carcinoma of the head and neck, or SCCHN, and types of non-small cell lung cancer (NSCLC), including both squamous cell and non-squamous cell NSCLCs. It's IMGN529 ADC is used for the treatment of cancers that highly express CD37, such as non-Hodgkin lymphoma, or NHL, and chronic lymphocytic leukemia. The Company's main competitors include Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. In addition to regulations in the U.S., the company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.
» More Articles for IMGN

Headlines

Articles On GuruFocus.com
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results Aug 06 2009 
ImmunoGen Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ImmunoGen's stock plunges after Roche's disappointing trial results prompts downgrade Dec 19 2014
Mid-Day Losers From December 19: ImmunoGen, NQ Mobile And More Dec 19 2014
Juno Therapeutics IPO Caps Big Year In Biotech Deals Dec 19 2014
Roche Drugs For Alzheimer's, Breast Cancer Disappoint Dec 19 2014
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half Dec 19 2014
ImmunoGen (IMGN) Stock Plummets to One-Year Low on Disappointing Breast Cancer Drug Results Dec 19 2014
Cramer's Mad Dash: Tale of two biotechs Dec 19 2014
Ahead of the Bell: ImmunoGen shares tumble Dec 19 2014
Ahead of the Bell: ImmunoGen shares tumble Dec 19 2014
6:06 am Immunogen reported that Roche (RHHBY) has announced... Dec 19 2014
ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial Dec 19 2014
ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial Dec 19 2014
ImmunoGen, Inc. Announces Webcast of Presentation at the 33rd Annual J.P. Morgan Healthcare... Dec 15 2014
IMMUNOGEN INC Files SEC form 8-K, Regulation FD Disclosure Dec 15 2014
ImmunoGen Reports Encouraging Data on Cancer Drug Dec 08 2014
ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and... Dec 06 2014
ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and... Dec 06 2014
ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual... Nov 24 2014
ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual... Nov 24 2014
ImmunoGen, Inc. Again Named One of The Boston Globe’s Top Places to Work Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK